Healthcare / Drug Manufacturers - Specialty & GenericBSE
$266.95
-0.70 (-0.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-168.3M · quality 39.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
51.4x
↑EV/EBITDA
52.1x
↑ROE
4.3%
↑Gross Margin
52.5%
↑Debt/Equity
1.05
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-27.3%
FCF CAGR
—
FCF margin
-93.1%
FCF / Net income
-9.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $194.0M · net income $18.4M · FCF $-180.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $194.0M | $194.0M | $536.4M | $522.6M | $504.4M |
| Net Income | $18.4M | $18.4M | $77.9M | $24.4M | $28.4M |
| EBITDA | $40.6M | $40.6M | $121.7M | $53.3M | $57.2M |
| EPS | 2.95 | 2.95 | 12.50 | 3.92 | 4.56 |
| Gross Margin | 52.5% | 52.5% | 50.5% | 29.7% | 33.4% |
| Operating Margin | 11.9% | 11.9% | 17.9% | 6.4% | 7.2% |
| Net Margin | 9.5% | 9.5% | 14.5% | 4.7% | 5.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.05 | 1.05 | 0.63 | 0.19 | 0.44 |
| Cash Flow | |||||
| Free Cash Flow | $-180.5M | $-180.5M | $-168.3M | $-7.9M | $-112.0M |
| Returns | |||||
| ROE | 4.3% | 4.3% | 18.6% | 7.1% | 9.0% |
| Valuation | |||||
| P/E | 51.44 | 51.44 | 14.66 | 16.88 | 23.14 |
| EV/EBITDA | 52.08 | 52.08 | 11.46 | 8.60 | 13.00 |
| P/B | 3.87 | 3.87 | 2.72 | 1.21 | 2.09 |
| Growth & Yield | |||||
| Revenue Growth | -63.8% | -63.8% | 2.6% | 3.6% | — |
| EPS Growth | -76.4% | -76.4% | 218.9% | -14.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
100.2%
EPS terminal req.
$23.69
Spread vs growth
-176.6%
5Y implied EPS CAGR
57.6%
EPS terminal req.
$28.66
Spread vs growth
-134.0%
10Y implied EPS CAGR
31.7%
EPS terminal req.
$46.16
Spread vs growth
-108.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.0%
Start / end P/E
20.2x → 90.5x
EPS bridge
12.50 → 2.95
Residual
-266.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.